A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

SpringerPlus
Katharina GunzerJean-Louis Misset

Abstract

Phase II, open-label study assessing the efficacy and safety of the ErbB family blocker afatinib combined with letrozole in estrogen receptor-positive metastatic breast cancer (MBC) patients who had progressed on letrozole monotherapy. Adult females (N = 28) received oral afatinib (50 [n = 7], 40 [n = 13] or 30 [n = 8] mg/day) plus letrozole 2.5 mg/day in 28-day cycles until disease progression. Primary endpoint was the progression-free rate at or after 16 weeks of afatinib. At 16 weeks, four patients remained on afatinib without progression; two of these were HER2 negative. Fifteen (54 %) patients had a best response of stable disease according to Response Evaluation Criteria in Solid Tumors. Median progression-free survival was 60, 107 and 79 days with 50, 40 and 30 mg/day afatinib, respectively. Diarrhea, asthenia, rash, mucosal inflammation and nausea were the most frequent adverse events. In this small, exploratory study, afatinib combined with letrozole was able to induce disease stabilization in 54 % of hormone-refractory MBC patients previously progressing on letrozole. NCT00708214.

References

Apr 20, 1990·Cell·A Ullrich, J Schlessinger
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Mar 24, 2000·Endocrine-related Cancer·M Dowsett
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Dec 18, 2001·Biopharmaceutics & Drug Disposition·C U PfisterU Hornberger
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Henning T MouridsenIan E Smith
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rachel SchiffC Kent Osborne
Jun 1, 2006·Cancer Chemotherapy and Pharmacology·Monica M MitaAmita Patnaik
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E SmithMitch Dowsett
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Oct 3, 2008·Journal of Hematology & Oncology·David Chu, Janice Lu
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Massimo CristofanilliPatrick J Magill
Mar 31, 2010·Clinical Journal of Oncology Nursing·Cynthia Frankel, Frances M Palmieri
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy A YapRuth Plummer
Jan 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·C Kent OsborneMark Sellers
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T

❮ Previous
Next ❯

Citations

Feb 16, 2017·BMC Genomics·Bernard Kok Bang LeeSok Ching Cheong
Jul 12, 2017·Expert Opinion on Drug Safety·Samuel MartelEvandro De Azambuja
Jul 30, 2016·Clinical Pharmacokinetics·Sven WindPeter Stopfer
Oct 31, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Denis M CollinsJohn Crown

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02115048

Software Mentioned

eLEcTRA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.